iBio CMO Molly Carr Receives 430,000-Share Award

What Happened

• Molly Carr, Chief Medical Officer of iBio, was granted a derivative award for 430,000 shares on July 31, 2026. The filing reports an acquisition price of $0.00 (transaction code A), indicating a grant of stock-based awards (options or RSUs) rather than an open-market purchase or sale. No cash value or exercise price is listed in the Form 4.

Key Details

• Transaction date: July 31, 2026 (reported on Form 4 filed Aug 4, 2026); filing was timely under the two-business-day rule.
• Reported amount: 430,000 shares granted at $0.00 (derivative award; transaction code A).
• Shares owned after transaction: Not specified in the filing.
• Footnotes:
  • F1 — Award was granted as an inducement outside the iBio, Inc. 2023 Omnibus Incentive Plan per Nasdaq Listing Rule 5635(c)(4).
  • F2 — Vesting: 25% on the one-year anniversary of the grant, then 6.25% every three months thereafter, contingent on continued employment.
• No indication this was an exercise or immediate sale; it is a future-compensatory award.

Context

• This was a compensation/retention award, not a market purchase — such grants are common for executives and vest over time. They don’t represent immediate stock buying or selling and only translate into owned shares if/when vested and, for options, exercised.